Dacomitinib APIs, available through Loncom Pharma, offer a potent option for the treatment of EGFR-mutated non-small cell lung cancers. As an irreversible pan-HER inhibitor, these APIs show efficacy in patients who have progressed on other targeted therapies.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
